Patterns of nicotinic receptor antagonism II: Cardiovascular effects in rats

Drug and Alcohol Dependence

Volumn 131, Issue 3, 2013, Pages 284-297

  Jutkiewicz, Emily M ^a   Rice, Kenner C ^c   Carroll, F Ivy ^d   Woods, James H ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d RTI INTERNATIONAL   (United States)

Author keywords

Cardiovascular effects; Nicotine; Nicotinic agonists; Rats

Indexed keywords

BUNGAROTOXIN RECEPTOR; CYTISINE; DIHYDRO BETA ERYTHROIDINE; EPIBATIDINE; HEXAMETHONIUM; MECAMYLAMINE; METHYLLYCACONITINE; NICOTINE TARTRATE; NICOTINIC RECEPTOR ALPHA4; NICOTINIC RECEPTOR BETA2; NICOTINIC RECEPTOR BLOCKING AGENT; VARENICLINE;

ANIMAL EXPERIMENT; ARTICLE; AUTONOMIC GANGLION; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CONSCIOUSNESS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HEART RATE; HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; TELEMETRY;

CARDIOVASCULAR EFFECTS; NICOTINE; NICOTINIC AGONISTS; RATS;

ANIMALS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; MALE; NICOTINIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC;

NICOTIANA TABACUM; RATTUS;

EID: 84881248718     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.12.021     Document Type: Article

References (70)

1. Aberger K., Chitravanshi V.C., Sapru H.N. Cardiovascular responses to microinjections of nicotine into the caudal ventrolateral medulla of the rat. Brain Res. 2001, 892:138-146.
2. Arslan B.Y., Ulus I.H., Savci V., Kiran B.K. Effects of intracerebroventricular injected choline on cardiovascular functions and sympathoadrenal activity. J. Cardiovasc. Pharmacol. 1991, 17:814-821.
3. Asghar K., Roth L.J. Entry and distribution of hexamethonium in the central nervous system. Biochem. Pharmacol. 1971, 20:2787-2790.
4. Baker E.R., Zwart R., Sher E., Millar N.S. Pharmacological properties of alpha9alpha10 nicotinic acetylcholine receptor revealed by heterologous expression of subunit chimeras. Mol. Pharmacol. 2004, 65:453-460.
5. Bibevski S., Zhou Y., McIntosh J.M., Zigmond R.E., Dunlap M.E. Functional nicotinic acetylcholine receptors that mediate ganglionic transmission in cardiac parasympathetic neurons. J. Neurosci. 2000, 20:5076-5082.
6. Buisson B., Gopalakrishnan M., Arneric S.P., Sullivan J.P., Bertrand D. Human alpha4beta2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: a patch-clamp study. J. Neurosci. 1996, 16:7880-7891.
7. Carroll F.I., Ma W., Deng L., Navarro H.A., Damaj M.I., Martin B.R. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 3'-(substituted phenyl)epibatidine analogues. Nicotinic partial agonists. J. Nat. Prod. 2010, 73:306-312.
8. Chandler C.J., Stolerman I.P. Discriminative stimulus properties of the nicotinic agonist cytisine. Psychopharmacology (Berl.) 1997, 129:257-264.
9. Chavez-Noriega L.E., Crona J.H., Washburn M.S., Urrutia A., Elliott K.J., Johnson E.C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 1997, 280:346-356.
10. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Huang J., Sands S.B., Davis T.I., Lebel L.A., Fox C.B., Shrikhande A., Heym J.H., Schaeffer E., Rollema H., Lu Y., Manbach R.S., Chambers L.K., Rovetti C.C., Schulz D.W., Tingley F.D., O'Neill B.T. Varenicline: an a4b2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 2005, 48:3474-3477.
11. Corrigall W.A., Coen K.M., Adamson K.L. Self-administered nicotine activates the mesolimic dopamine system through the ventral tegmental area. Brain Res. 1994, 653:278-284.
12. Cunningham C.S., McMahon L.R. The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: difference in a4b2 nicotinic receptor activation. Eur. J. Pharmacol. 2011, 654:47-52.
13. Cunningham C.S., Javors M.A., McMahon L.R. Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys. J. Pharmacol. Exp. Ther. 2012, 341:840-849.
14. Deck J., Bibevski S., Gnecchi-Ruscone T., Bellina V., Montano N., Dunlap M.E. Alpha7-nicotinic acetylcholine receptor subunit is not required for parasympathetic control of the heart in the mouse. Physiol. Genomics 2005, 22:86-92.
15. Del Signore A., Gotti C., Rizzo A., Moretti M., Paggi P. Nicotinic acetylcholine receptor subtypes in the rat sympathetic ganglion: pharmacological characterization, subcellular distribution and effect of pre- and postganglionic nerve crush. J. Neuropathol. Exp. Neurol. 2004, 63:138-150.
16. Delaunois A., Dedoncker P., Hanon E., Guyaux M. Repeated assessment of cardiovascular and respiratory functions using combined telemetry and whole-body plethysmography in the rat. J. Pharmacol. Toxicol. Methods 2009, 60:117-129.
17. Donny E.C., Caggiula A.R., Sweitzer M., Chaudhri N., Gharib M., Sved A.F. Self-administered and yoked nicotine produce robust increases in blood pressure and changes in heart rate with modest effects of behavioral contingency in rats. Pharmacol. Biochem. Behav. 2011, 99:459-467.
18. Eaton J.B., Peng J.-H., Schroeder K.M., George A.A., Fryer J.D., Krishnan C., Buhlman L., Kuo Y.-P., Steinlein O., Lukas R.J. Characterization of human a4b2-nicotnic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol. Pharmacol. 2003, 64:1283-1294.
19. Ferreira M., Singh A., Dretchen K.L., Kellar K.J., Gillis R.A. Brainstem nicotinic receptor subtypes that influence intragastric and arterial blood pressures. J. Pharmacol. Exp. Ther. 2000, 294:230-238.
20. Franceschini D., Orr-Urtreger A., Yu W., Mackey L.Y., Bond R.A., Armstrong D., Patrick J.W., Beaudet A.L., De Biasi M. Altered baroreflex responses in alpha7 deficient mice. Behav. Brain Res. 2000, 113:3-10.
21. Genzen J.R., Van Cleve W., McGehee D.S. Dorsal root ganglion neurons express multiple nicotinic acetylcholine receptor subtypes. J. Neurophysiol. 2001, 86:1773-1782.
22. Gommans J., Stolerman I.P., Shoaib M. Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6J mice. Neuropharmacology 2000, 39:2840-2847.
23. Gotti C., Riganti L., Vailati S., Clementi F. Brain neuronal nicotinic receptor as new targets for drug discovery. Curr. Pharm. Des. 2006, 12:407-428.
24. Haas M., Kubler W. Nicotine and sympathetic neurotransmission. Cardiovasc. Drugs Ther. 1996, 10:657-665.
25. Hall M., Zerbe L., Leonard S., Freedman R. Characterization of [3H]cytisine binding to human brain membranes preparations. Brain Res. 1993, 600:127-133.
26. Harvey S.C., Luetje C.W. Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor beta subunits. J. Neurosci. 1996, 16:3798-3806.
27. Harvey S.C., Maddoz F.N., Luetje C.W. Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits. J. Neurochem. 1996, 67:1953-1959.
28. Henningfield J.E., Miyasato K., Jasinski D.R. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J. Pharmacol. Exp. Ther. 1985, 234:1-12.
29. Houdi A.A., Dowell R.T., Diana J.N. Cardiovascular responses to cigarette smoke exposure in restrained conscious rats. J. Pharmacol. Exp. Ther. 1995, 275:646-653.
30. Jutkiewicz E.M., Brooks E., Kynaston A., Rice K.C., Woods J.H. Patterns of nicotinic receptor antagonism: nicotine discrimination studies. J. Pharmacol. Exp. Ther. 2011, 339:194-202.
31. Kaïdi S., Brutel F., Van Deun F., Kramer K., Remie R., Dewe W., Remusat P., Delaunois A., Depelchin O. Comparison of two methods (left carotid artery and abdominal aorta) for surgical implantation of radiotelemetry devices in CD-1 mice. Lab. Anim. 2007, 41:388-402.
32. Khan I.M., Printz M.P., Yaksh T.L., Taylor P. Augmented responses to intrathecal nicotinic agonists in spontaneous hypertension. Hypertension 1994, 24:611-619.
33. Kirstein S.L., Insel P.A. Autonomic nervous system pharmacogenomics: a progress report. Pharmacol. Rev. 2004, 56:31-52.
34. Koch A., Hoffman K., Steck W., Horsch A., Hengen N., Mörl H., Harenberg J., Spohr U., Weber E. Acute cardiovascular reactions after cigarette smoking. Atherosclerosis 1980, 35:67-75.
35. Kubo T., Misu Y. Changes in arterial blood pressure after microinjection of nicotine into the dorsal area of the medulla oblongata of the rat. Neuropharmacology 1981, 20:521-524.
36. Le Foll B., Chefer S.I., Kimes A.S., Shumway D., Stein E.A., Mukhin A.G., Goldberg S.R. Baseline expression of alpha4beta2* nicotinic acetylcholine receptors predicts motivation to self-administer nicotine. Biol. Psychiatry 2009, 65:714-716.
37. LeSage M.G., Shelley D., Ross J.T., Carroll F.I., Corrigall W.A. Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. Pharmacol. Biochem. Behav. 2009, 91:461-467.
38. Li Y.F., LaCroix C., Freeling J. Specific subtypes of nicotinic cholinergic receptors involved in sympathetic and parasympathetic cardiovascular responses. Neurosci. Lett. 2009, 462:20-23.
39. Li Y.F., LaCroix C., Freeling J. Cytisine induced autonomic cardiovascular responses via activations of different nicotinic receptors. Auton. Neurosci. 2010, 154:14-19.
40. Liu X., Palmatier M.I., Caggiula A.R., Donny E.C., Sved A.F. Reinforcement enhancing effect of nicotine and its attenuation by nicotinic antagonists in rats. Psychopharmacology (Berl.) 2007, 194:463-473.
41. Malin D.H., Lake J.R., Schopen C.K., Kirk J.W., Sailer E.E., Lawless B.A., Upchurch T.P., Shenoi M., Rajan N. Nicotine abstinence syndrome precipitated by central but not peripheral hexamethonium. Pharmacol. Biochem. Behav. 1997, 58:695-699.
42. Mansbach R.S., Chambers L.K., Rovetti C.C. Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine. Psychopharmacology (Berl.) 2000, 148:234-242.
43. Mao D., Yasuda R.P., Fan H., Wolfe B.B., Kellar K.J. Heterogeneity of nicotinic cholinergic receptors in rat superior cervical and nodose ganglia. Mol. Pharmacol. 2006, 70:1693-1699.
44. Marano G., Ramirez A., Mori I., Ferrari A.U. Sympathectomy inhibits the vasoactive effects of nicotine in conscious rats. Cardiovasc. Res. 1999, 42:201-205.
45. Marks M.J., Robinson S.F., Collins A.C. Nicotinic agonists differ in activation and desensitization of 86Rb+ efflux from mouse thalamic synaptosomes. J. Pharmacol. Exp. Ther. 1996, 277:1383-1396.
46. Mihalak K.B., Carroll F.I., Leutje C.W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol. Pharmacol. 2006, 70:801-805.
47. Murota Y., Fujii M., Sugiyama Y., Funabashi T., Takahashi T., Goshima Y. DOPA cyclohexyl ester, a DOPA antagonist, blocks the depressor responses elicited by microinjections of nicotine into the nucleus tractussolitarii of rats. Neurosci. Lett. 2008, 422:114-117.
48. Nadeau R.A., James T.N. Effects of nicotine on heart rate studied by direct perfusion of sinus node. Am. J. Physiol. 1967, 212:911-916.
49. Perry D.C., Xiao Y., Nguyen H.N., Musachio J.L., Dávila-García M.I., Kellar K.J. Measuring nicotinic receptors with characteristics of a4b2, a3b2 and a3b4 subtypes in rat tissues by autoradiography. J. Neurochem. 2002, 82:468-481.
50. Poth K., Nutter T.J., Cuevas J., Parker M.J., Adams D.J., Luetje C.W. Heterogeneity of nicotinic receptor class and subunit mRNA expression among individual parasympathetic neurons from rat intracardiac ganglia. J. Neurosci. 1997, 17:586-596.
51. Reavill C., Walther B., Stolerman I.P., Testa B. Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology 1990, 29:619-624.
52. Robertson D., Tseng C.J., Appalsamy M. Smoking and mechanisms of cardiovascular control. Am. Heart J. 1988, 115:258-263.
53. Rollema H., Chambers L.K., Coe J.W., Glowa J., Hurst R.S., Lebel L.A., Lu Y., Mansbach R.S., Mather R.J., Rovetti C.C., Sands S.B., Schaeffer E., Schulz D.W., Tingley F.D., Williams K.E. Pharmacological profile of the a4b2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007, 52:985-994.
54. Rose J.E., Behm F.M., Westman E.C., Johnson M. Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacol. Biochem. Behav. 2000, 67:71-81.
55. Salminen O., Murphy K.L., McIntosh J.M., Drago J., Marks M.J., Collins A.C., Grady S.R. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol. Pharmacol. 2004, 65:1526-1535.
56. Shoaib M., Gommans J., Morley A., Stolerman I.P., Grailhe R., Changeux J.P. The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion. Neuropharmacology 2002, 42:530-539.
57. Singh S., Loke Y.K., Spangler J.G., Furberg C.D. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011, 183:1359-1366.
58. Sloan J.W., Martin W.R., Bostwick M., Hook R., Wala E. The comparative binding characteristics of nicotinic ligands and their pharmacology. Pharmacol. Biochem. Behav. 1988, 30:255-267.
59. Smith J.W., Mogg A., Tafi E., Peacey E., Pullar I.A., Szekeres P., Tricklebank M. Ligands selective for a4b2 but not a3b4 or a7 nicotinic receptors generalize to the nicotine discriminative stimulus in the rat. Psychopharmacology (Berl.) 2007, 190:157-170.
60. Smith J.W., Stolerman I.P. Recognising nicotine: the neurobiological basis of nicotine discrimination. Handb. Exp. Pharmacol. 2009, 192:295-333.
61. Sofuoglu M., Yoo S., Hill K.P., Mooney M. Self-administration of intravenous nicotine in male and female cigarette smokers. Neuropsychopharmacology 2008, 33:715-720.
62. Soria R., Stapleton J.M., Gilson S.F., Sampson-Cone A., Henningfield J.E., London E.D. Subjective and cardiovascular effects of intravenous nicotine in smokers and non-smokers. Psychopharmacology (Berl.) 1996, 128:221-226.
63. Spohr U., Hofmann K., Steck W., Harenberg J., Walter E., Hengen N., Augustin J., Mörl H., Koch A., Horsch A., Weber E. Evaluation of smoking-induced effects on sympathetic, hemodynamic and metabolic variables with respect to plasma nicotine and COHb levels. Atherosclerosis 1979, 33:271-283.
64. Stolerman I.P., Pratt J.A., Garcha H.S., Giardini V., Kumar R. Nicotine cue in rats analysed with drugs acting on cholinergic and 5-hydroxytryptamine mechanisms. Neuropharmacology 1983, 22:1029-1037.
65. Stolerman I.P., Chandler C.J., Garcha H.S., Newton J.M. Selective antagonism of behavioural effects of nicotine by dihydro-b-erythroidine in rats. Psychopharmacology (Berl.) 1997, 129:390-397.
66. Tachmes L., Fernandez R.J., Sackner M.A. Hemodynamic effects of smoking cigarettes of high and low nicotine content. Chest 1978, 74:243-246.
67. Tseng C.J., Appalsamy M., Robertson D., Mosqueda-Garcia R. Effects of nicotine on brain stem mechanisms of cardiovascular control. J. Pharmacol. Exp. Ther. 1993, 265:1511-1518.
68. Watkins S.S., Epping-Jordan M.P., Koob G.F., Markou A. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol. Biochem. Behav. 1999, 62:743-751.
69. Williams J.M., Steinberg M.B., Steinberg M.L., Gandhi K.K., Ulpe R., Foulds J. Varenicline for tobacco dependence: panacea or plight?. Expert Opin. Pharmacother. 2011, 12:1799-1812.
70. Zaniewska M., McCreary A.C., Przegaliński E., Filip M. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. Eur. J. Pharmacol. 2006, 540:96-106.